Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea Biotherapeutics, Inc. (not Spyre Therapeutics, Inc.) on July 8, 2021. The report discloses the appointment of a new Chief Financial Officer effective July 6, 2021.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Jonathan Alspaugh as Chief Financial Officer, effective July 6, 2021. Mr. Alspaugh previously served as a Managing Director at Evercore Inc. and an Associate at Barclays Capital Inc.
Compensation and Management Commentary
- Base Salary: $400,008 annually.
- Cash Bonus: Eligible for up to 40% of the annual base salary, subject to performance criteria.
- Stock Options: Granted an option to purchase 160,000 shares of common stock at the closing sale price on July 6, 2021.
- Vesting Schedule: 25% vests one year after the grant date; the remaining 75% vests monthly (1/48th per month) thereafter, contingent on continued service.
- Indemnification: The Company entered into its standard form of indemnification agreement with Mr. Alspaugh.
Investor Verification Checklist
- Verify the exact closing stock price on July 6, 2021, to determine the exercise price of the 160,000 stock options.
- Review the specific performance criteria required to achieve the 40% cash bonus.
- Confirm the absence of any undisclosed family relationships or material interests involving the new CFO as stated in the filing.
- Check subsequent filings for any changes to the vesting schedule or employment terms.